J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More

 
• By Mandy Jackson, Andrew McConaghie, and Jessica Merrill

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A. 

Alamo Square, San Fransisco, CA
Highlights from Day 2 at J.P. Morgan. • Source: Shutterstock

More from Strategy

More from Business